These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 20473651)

  • 1. Comparative hemodynamic effects of levosimendan alone and in conjunction with 4-aminopyridine or calcium chloride in a rodent model of severe verapamil poisoning.
    Graudins A; Wong KK
    J Med Toxicol; 2010 Jun; 6(2):85-93. PubMed ID: 20473651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity.
    Graudins A; Najafi J; Rur-SC MP
    Clin Toxicol (Phila); 2008 Jan; 46(1):50-6. PubMed ID: 17926153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levosimendan infusion improves cardiac output but not blood pressure in a rodent model of severe metoprolol toxicity.
    Kalam Y; Graudins A
    Hum Exp Toxicol; 2012 Sep; 31(9):955-63. PubMed ID: 22249394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levosimendan does not improve cardiac output or blood pressure in a rodent model of propranolol toxicity when administered using various dosing regimens.
    Kalam Y; Graudins A
    Int J Toxicol; 2012 Mar; 31(2):166-74. PubMed ID: 22422349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levosimendan does not improve survival time in a rat model of verapamil toxicity.
    Abraham MK; Scott SB; Meltzer A; Barrueto F
    J Med Toxicol; 2009 Mar; 5(1):3-7. PubMed ID: 19191208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of fructose-1,6-diphosphate on haemodynamic parameters and survival in a rodent model of propranolol and verapamil poisoning.
    Kalam Y; Graudins A
    Clin Toxicol (Phila); 2012 Aug; 50(7):546-54. PubMed ID: 22871053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.
    Kivikko M; Lehtonen L
    Curr Pharm Des; 2005; 11(4):435-55. PubMed ID: 15725064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.
    Banfor PN; Preusser LC; Campbell TJ; Marsh KC; Polakowski JS; Reinhart GA; Cox BF; Fryer RM
    Am J Physiol Heart Circ Physiol; 2008 Jan; 294(1):H238-48. PubMed ID: 17982006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levosimendan in regional myocardial ischemia.
    Pieske B
    Cardiovasc Drugs Ther; 2002 Sep; 16(5):379-81. PubMed ID: 12656119
    [No Abstract]   [Full Text] [Related]  

  • 10. Functional role of potassium channels in the vasodilating mechanism of levosimendan in porcine isolated coronary artery.
    Pataricza J; Krassói I; Höhn J; Kun A; Papp JG
    Cardiovasc Drugs Ther; 2003 Mar; 17(2):115-21. PubMed ID: 12975592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New treatment methods in verapamil poisoning: experimental studies.
    Magdalan J
    Pol J Pharmacol; 2003; 55(3):425-32. PubMed ID: 14506322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemodynamic interactions between the novel calcium sensitiser levosimendan and isosorbide-5-mononitrate in healthy subjects.
    Sundberg S; Lehtonen L
    Eur J Clin Pharmacol; 2000; 55(11-12):793-9. PubMed ID: 10805056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of levosimendan in experimental verapamil-induced myocardial depression.
    Kurola J; Leppikangas H; Magga J; Lindgren L; Kiviniemi V; Rutanen J; Ruokonen E
    Scand J Trauma Resusc Emerg Med; 2010 Mar; 18():12. PubMed ID: 20222974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Levosimendan: dual mechanisms for acute heart failure...and beyond?
    Ng TM; Akhter MW
    Minerva Cardioangiol; 2005 Dec; 53(6):565-84. PubMed ID: 16333239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril.
    Antila S; Eha J; Heinpalu M; Lehtonen L; Loogna I; Mesikepp A; Planken U; Sandell EP
    Eur J Clin Pharmacol; 1996; 49(6):451-8. PubMed ID: 8706769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and milrinone: comparative effects on peripheral resistance, cardiac output, dP/dt, pulse rate, and blood pressure.
    Segreti JA; Marsh KC; Polakowski JS; Fryer RM
    J Pharmacol Exp Ther; 2008 Apr; 325(1):331-40. PubMed ID: 18171907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemodynamic and neurohumoral effects of levosimendan, a new calcium sensitizer, at rest and during exercise in healthy men.
    Sundberg S; Lilleberg J; Nieminen MS; Lehtonen L
    Am J Cardiol; 1995 May; 75(15):1061-6. PubMed ID: 7747690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties.
    Lehtonen LA
    Expert Opin Investig Drugs; 2001 May; 10(5):955-70. PubMed ID: 11322869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levosimendan: A promising agent for the treatment of hospitalized patients with decompensated heart failure.
    Lehtonen L
    Curr Cardiol Rep; 2000 May; 2(3):233-43. PubMed ID: 10980898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure.
    Lehtonen L
    Curr Heart Fail Rep; 2004 Sep; 1(3):136-44. PubMed ID: 16036037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.